LABT$0.1841-0.49%
Lakewood-Amedex Biotherapeutics Inc.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$436.3K
Float & O/S:
Inst Own:
DilutionScan read 19 of Lakewood-Amedex Biotherapeutics Inc.'s SEC filings and found 12 warrant series, 4 convertibles, 3 S-1 registrations and 1 completed offering on file for LABT. The latest dilution event on file is a registration statement on Sep 24, 2026. Analysis updated Oct 13, 2026.
Signal8 Summary
LABT
Pre-revenue biotech, tight cash, fresh reverse split
Snapshot
Lakewood-Amedex is a clinical-stage biotech with no products on the market and no revenue. It lost $3.8M in FY 2025 and burned $1.9M in free cash flow, leaving just $236K in cash against $1.7M of debt.
What's Happening Right Now
- : A preliminary proxy for the September 22, 2026 annual meeting seeks to raise authorized shares from 12.5 million to 100 million and pre-authorize another reverse split (up to 1-for-20) to stay compliant with Nasdaq listing rules.
- : The company highlighted resistance data showing Nu-3 has a high barrier to resistance, tying the release to a federal antibiotic-resistance action plan.
- : Lakewood-Amedex announced preclinical safety data supporting dose selection (2%, 5%, 10% gel) for its upcoming Phase 2a trial of Nu-3 gel in infected diabetic foot ulcers.
- : Lakewood-Amedex secured a new Australian composition-of-matter patent covering additional Bisphosphocin compounds being explored for UTIs and pulmonary infections.
- : On June 22, 2026, the company completed a 1-for-10 reverse stock split, cutting shares outstanding from about 17.5 million to about 1.75 million.
